(19)
(11) EP 3 735 267 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
09.11.2022 Bulletin 2022/45

(45) Mention of the grant of the patent:
14.09.2022 Bulletin 2022/37

(21) Application number: 19705386.1

(22) Date of filing: 04.01.2019
(51) International Patent Classification (IPC): 
A61K 39/00(2006.01)
A61K 31/513(2006.01)
A61K 31/555(2006.01)
 A61K 31/4745(2006.01)
A61K 31/519(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/4745; A61K 31/513; A61K 31/519; C07K 16/22; A61K 2039/505; C07K 2317/24; C07K 2317/73; C07K 2317/76; A61P 35/00; C07K 16/00
 
C-Sets:
  1. A61K 31/4745, A61K 2300/00;
  2. A61K 31/513, A61K 2300/00;
  3. A61K 31/519, A61K 2300/00;
(86) International application number:
PCT/IB2019/000008
(87) International publication number:
WO 2019/135157 (11.07.2019 Gazette 2019/28)

(54)

ADMINISTRATION OF MULTIPLE BOLUSES OF [6R] MTHF IN A 5-FLUOROURACIL-BASED CHEMOTHERAPY

[6R]-MTHF-BOLUS-MEHRFACHVERABREICHUNG IN 5-FLUORURACIL-BASIERTER CHEMOTHERAPIE

ADMINISTRATION DE BOLUS MULTIPLES [6R]-MTHF DANS UNE CHIMIOTHÉRAPIE À BASE DE 5-FLUOROURACILE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 05.01.2018 WO PCT/EP2018/050274
03.04.2018 US 201862651910 P
19.11.2018 US 201862769289 P

(43) Date of publication of application:
11.11.2020 Bulletin 2020/46

(73) Proprietor: Isofol Medical AB
413 46 Göteborg (SE)

(72) Inventors:
  • Ganlöv, Karin
    411 25 Göteborg (SE)
  • Östberg, Magnus
    416 53 Göteborg (SE)
  • Lindberg, Per L.
    413 01 Göteborg (SE)
  • Sundén, Gunnel E.
    41301 Gothenburg (SE)
  • Gustavsson, Bengt
    426 79 Vastra Frolunda (SE)

(74) Representative: AWA Denmark A/S 
Strandgade 56
1401 Copenhagen K
1401 Copenhagen K (DK)


(56) References cited: : 
WO-A2-2005/097086
 WO-A2-2007/064968
   
  • Muhammad Wasif Saif ET AL: "Phase III Multicenter Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor / 5-Fluorouracil/Bevacizumab Versus Leucovorin/ 5-Fluorouracil/Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma", Clinical Colorectal Cancer, 1 September 2006 (2006-09-01), pages 229-234, XP055358951, Retrieved from the Internet: URL:http://www.clinical-colorectal-cancer. com/article/S1533-0028(11)70289-4/pdf [retrieved on 2017-03-27]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).